There is an increasing body of clinical evidence linking pharmacogenetic (PGx) variability of CYP2D6 and CYP2C19 to drug blood concentrations [4,5], the treatment response [4,6], and the remission rates [6] in patients with depression. Here, CYP2C19 is linked to depressive disorder.